Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Si Lian Kang + esomeprazole + amoxicillin + furazolidone + bismuth potassium citrate
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Si Lian Kang + esomeprazole + amoxicillin + furazolidone + bismuth potassium citrate is a combination therapeutic regimen used for the eradication of Helicobacter pylori infection. It consists of Si Lian Kang, a probiotic tetrad containing live Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, and Bacillus cereus, administered alongside a standard bismuth-containing quadruple therapy. The quadruple therapy component includes the proton pump inhibitor esomeprazole magnesium, the antibiotics amoxicillin and furazolidone, and the mucosal protective agent bismuth potassium citrate. This combination is designed to improve H. pylori eradication rates and minimize antibiotic-associated side effects, such as gastrointestinal dysbiosis and diarrhea, by replenishing beneficial gut bacteria during the intensive treatment course.
- Brand names
- Si Lian KangA Mo XianLi Zhu De Le
- Other names
- Bifidobacterium quadruple live bacteria tablets plus Helicobacter pylori quadruple eradication therapyBifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapySi Lian Kang in H. pylori eradication therapy
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on Si Lian Kang + esomeprazole + amoxicillin + furazolidone + bismuth potassium citrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Si Lian Kang + esomeprazole + amoxicillin + furazolidone + bismuth potassium citrate.